清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

388 Efficacy and safety of roflumilast foam 0.3% in patients with seborrheic dermatitis in a phase 3 trial: assessment of pruritus

罗氟司特 耐受性 医学 临床终点 随机对照试验 内科学 随机化 头皮 不利影响 胃肠病学 皮肤病科 慢性阻塞性肺病
作者
Andrew Blauvelt,Zoe Diana Draelos,Melinda Gooderham,Edward L. Lain,Angela Yen Moore,Kim Alexander Papp,Matthew Zirwas,David A. Krupa,Patrick Burnett,David R. Berk,David H. Chu
出处
期刊:British Journal of Dermatology [Oxford University Press]
卷期号:188 (Supplement_3)
标识
DOI:10.1093/bjd/ljad162.014
摘要

Abstract Itch is a major complaint among patients with seborrheic dermatitis (SD). Roflumilast is a selective, nonsteroidal, highly potent phosphodiesterase-4 inhibitor under investigation as a once-daily foam for treatment of SD. This phase 3 randomized, parallel-group, double-blind, vehicle-controlled trial (NCT04973228) was conducted in patients ≥9 years old with at least moderate SD affecting scalp and/or nonscalp areas. Patients were randomized 2 : 1 to apply once-daily roflumilast foam 0.3% (n = 304) or vehicle (n = 153) for 8 weeks. The primary efficacy endpoint was Investigator Global Assessment (IGA) success (IGA of Clear or Almost Clear plus ≥2-grade improvement from baseline) at Week 8. Secondary efficacy endpoints included Worst Itch Numeric Rating Scale (WI-NRS), which was completed daily by patients. Safety and local tolerability were also evaluated. Overall, significantly more roflumilast-treated patients than vehicle-treated patients achieved IGA success (79.5% vs. 58.0%; P < 0.0001) and IGA status of Clear (50.6% vs. 27.7%; P < 0.0001) at Week 8. Significantly greater percentages of roflumilast- than vehicle-treated patients had ≥4-point improvement on WI-NRS at Weeks 2 (32.7% vs. 15.5%; P = 0.0016), 4 (47.6% vs. 29.1%; P = 0.0007) and 8 (62.8% vs. 40.6%; P = 0.0001). Greater improvement in itch was observed among roflumilast-treated patients as early as 48 h after the first application (mean percent change from baseline: −27.87% vs. −13.11%; nominal P = 0.0024). Local tolerability and safety were favorable. Once-daily roflumilast foam provided improvement across multiple efficacy endpoints including rapid itch improvement, while demonstrating favorable safety and tolerability.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
cyj完成签到 ,获得积分10
3秒前
打打的应助被Wang采纳,获得10
16秒前
24秒前
30秒前
勤劳的翩跹完成签到,获得积分10
30秒前
文静的丹彤完成签到,获得积分10
31秒前
TingtingGZ发布了新的文献求助10
34秒前
蓝意完成签到,获得积分0
36秒前
李健的应助被TingtingGZ采纳,获得10
41秒前
英姑的应助被TingtingGZ采纳,获得10
41秒前
科研通AI6.2的应助被TingtingGZ采纳,获得10
41秒前
上官若男的应助被TingtingGZ采纳,获得10
42秒前
Hello的应助被TingtingGZ采纳,获得10
42秒前
科研通AI65的应助被TingtingGZ采纳,获得10
42秒前
万能图书馆的应助被TingtingGZ采纳,获得10
42秒前
molihuakai的应助被TingtingGZ采纳,获得10
42秒前
李健的小迷弟的应助被TingtingGZ采纳,获得30
42秒前
GingerF的应助被TingtingGZ采纳,获得200
42秒前
49秒前
快乐的稚晴完成签到,获得积分10
58秒前
紫熊完成签到,获得积分10
1分钟前
热情菲鹰完成签到,获得积分10
1分钟前
Luoyan完成签到,获得积分10
1分钟前
1分钟前
优雅的傲柏完成签到,获得积分10
1分钟前
1分钟前
我想进步完成签到,获得积分10
1分钟前
坚强含烟完成签到,获得积分10
1分钟前
龙龙发布了新的文献求助10
1分钟前
1分钟前
1分钟前
随心所欲完成签到 ,获得积分10
1分钟前
Ava的应助被龙龙采纳,获得10
1分钟前
怕孤单的雪瑶完成签到,获得积分10
1分钟前
陈荆洲完成签到,获得积分10
2分钟前
2分钟前
从容的绿蝶完成签到,获得积分10
2分钟前
如意夏寒完成签到,获得积分10
2分钟前
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173194
求助须知:如何正确求助?哪些是违规求助? 9565558
关于积分的说明 21780476
捐赠科研通 7767279
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555697
邀请新用户注册赠送积分活动 2476682